+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06060613

Phase 12 Open-Label Study of OBX-115 Tumor-Infiltrating Lymphocytes in Adults with Advanced Solid Tumors

Led by Obsidian Therapeutics, Inc. · Updated on 2026-11-03

254

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of an experimental treatment called OBX-115 in adults with advanced solid tumors, including metastatic melanoma and non-small cell lung cancer. This Phase 12 open-label study aims to understand how well OBX-115 works and how tolerable it is for patients who have progressed after prior therapies, with assessments guided by established cancer response criteria RECIST v1.1. Participants will undergo conditioning therapy including lymphodepletion with cyclophosphamide and fludarabine before receiving an infusion of OBX-115, which is made from their own tumor samples. Following the infusion, they will receive short courses of acetazolamide. The study includes multiple cohorts with specific treatment criteria, and researchers will monitor responses, disease control, progression-free survival, and overall survival over time. During the trial, participants will have tumor samples collected and receive regular evaluations including radiographic scans to measure tumor response and progression. Safety assessments will track side effects and adverse events, while investigators will document treatment tolerability and response duration. The study can last up to two years for some outcome assessments, and participants will be closely monitored for disease progression and survival throughout this period.

CONDITIONS

Brief Title

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Research Team

O

Obsidian Therapeutics

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here